Achieve Life Sciences, Inc. QUIT
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 52.81% | 149.04% | 23.70% | 121.84% | 92.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.77% | 46.40% | -18.85% | 20.84% | 17.86% |
| Operating Income | -39.77% | -46.40% | 18.85% | -20.84% | -17.86% |
| Income Before Tax | 16.14% | -487.90% | 20.73% | -18.62% | -15.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.14% | -487.90% | 20.73% | -18.62% | -15.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.14% | -487.90% | 20.73% | -18.62% | -15.42% |
| EBIT | -39.77% | -46.40% | 18.85% | -20.84% | -17.86% |
| EBITDA | -39.88% | -46.59% | 18.91% | -20.95% | -17.96% |
| EPS Basic | 59.45% | -118.05% | 48.49% | 23.15% | 22.27% |
| Normalized Basic EPS | 59.28% | -119.48% | 46.67% | 20.86% | 20.65% |
| EPS Diluted | 59.45% | -118.05% | 48.49% | 23.15% | 22.27% |
| Normalized Diluted EPS | 59.28% | -119.48% | 46.67% | 20.86% | 20.65% |
| Average Basic Shares Outstanding | 106.75% | 169.60% | 53.90% | 54.38% | 48.50% |
| Average Diluted Shares Outstanding | 106.75% | 169.60% | 53.90% | 54.38% | 48.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |